A multicenter, open-label, phase II study of the pharmacokinetics and safety of the 100 Mcg misoprostol vaginal insert (MVI 100) in women requiring cervical ripening and induction of labor

Trial Profile

A multicenter, open-label, phase II study of the pharmacokinetics and safety of the 100 Mcg misoprostol vaginal insert (MVI 100) in women requiring cervical ripening and induction of labor

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2013

At a glance

  • Drugs Misoprostol (Primary)
  • Indications Labour disorders; Labour induction
  • Focus Pharmacokinetics
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 15 Jun 2012 Actual patient number is 0 according to ClinicalTrials.gov.
    • 18 Mar 2008 The expected completion date for this trial is now 1 Dec 2008.
    • 12 Mar 2008 Status changed from initiated to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top